Synthetic routes to nanomaterials containing anthracyclines: noncovalent systems
Chemotherapy still constitutes a basic treatment for various types of cancer. Anthracyclines are effective antineoplastic drugs that are widely used in clinical practice. Unfortunately, they are characterized by high systemic toxicity and lack of tumour selectivity. A promising way to enhance treatm...
Gespeichert in:
Veröffentlicht in: | Biomaterials science 2018-09, Vol.6 (1), p.2552-2565 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Chemotherapy still constitutes a basic treatment for various types of cancer. Anthracyclines are effective antineoplastic drugs that are widely used in clinical practice. Unfortunately, they are characterized by high systemic toxicity and lack of tumour selectivity. A promising way to enhance treatment effectiveness and reduce toxicity is the synthesis of systems containing anthracyclines either in the form of complexes for the encapsulation of active drugs or their covalent conjugates with inert carriers. In this respect nanotechnology offers an extensive spectrum of possible solutions. In this review, we discuss recent advances in the development of anthracycline prodrugs based on nanocarriers such as copolymers, lipids, DNA, and inorganic systems. The review focuses on the chemical architecture of the noncovalent nanocarrier-drug systems.
Anthracyclines are very effective antibiotics widely used in chemotherapy; however, they also exert serious side effects. An important pathway to limit their general toxicity is encapsulation within nanocarriers, as exemplified in the graphics. It is a hot research subject with over 80 papers in the last 5 years. |
---|---|
ISSN: | 2047-4830 2047-4849 |
DOI: | 10.1039/c8bm00739j |